

Trial record **4 of 13** for: bazarbashi[◀ Previous Study](#) | [Return to List](#) | [Next Study ▶](#)

A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer



The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT01311050

Recruitment Status ⓘ : Unknown

Verified December 2011 by King Faisal Specialist Hospital & Research Center.

Recruitment status was: Recruiting

First Posted ⓘ : March 9, 2011**Last Update Posted** ⓘ : December 13, 2011**Sponsor:**

King Faisal Specialist Hospital & Research Center

Information provided by (Responsible Party):

King Faisal Specialist Hospital & Research Center

[Study Details](#)[Tabular View](#)[No Results Posted](#)[Disclaimer](#)[How to Read a Study Record](#)

Study Description

Go to **Brief Summary:**

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Condition or disease ⓘ	Intervention/treatment ⓘ
Metastatic Colorectal Cancer	Drug: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Detailed Description:

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Study Design

Go to 

Study Type ⓘ :

Observational

Estimated Enrollment ⓘ :

46 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Study Start Date ⓘ :

January 2009

Resource links provided by the National Library of Medicine



[Drug Information](#) available for: [Oxaliplatin](#) [Irinotecan](#) [Irinotecan hydrochloride](#) [Capecitabine](#) [Bevacizumab](#)

[U.S. FDA Resources](#)

Groups and Cohorts

Go to 

Intervention Details:

- Drug: Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Outcome Measures

Go to 

Eligibility Criteria

Go to 

Information from the National Library of Medicine



Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies](#).

Ages Eligible for Study:

14 Years to 85 Years (Child, Adult, Older Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

Metastatic Colorectal Cancer

Criteria

Inclusion Criteria:

- Patients with diagnosed Metastatic Colorectal Cancer

Exclusion Criteria:

- Patients with diagnosis other than Metastatic Colorectal Cancer

Contacts and Locations

Go to 

Information from the National Library of Medicine



To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

*Please refer to this study by its ClinicalTrials.gov identifier (NCT number): **NCT01311050***

Contacts

Contact: Shouki **Bazarbashi**, M.D. +966-1-4423949

Locations

Saudi Arabia

Kfsh & Rc **Recruiting**
Riyadh, Saudi Arabia

Sponsors and Collaborators

King Faisal Specialist Hospital & Research Center

Investigators

Principal Investigator: Shouki **Bazarbashi**, M.D. KFSH & RC

More Information

Go to 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

[Elshenawy MA, Badran A, Aljubran A, Alzahrani A, Rauf MS, Eldali A, Bazarbashi S. Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer. World J Surg Oncol. 2020 Jul 8;18\(1\):163. doi: 10.1186/s12957-020-01930-8.](#)

[Bazarbashi S, Aljubran A, Alzahrani A, Mohieldin A, Soudy H, Shoukri M. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer. Cancer Med. 2015 Oct;4\(10\):1505-13. doi: 10.1002/cam4.497. Epub 2015 Jul 24.](#)

Responsible Party:

King Faisal Specialist Hospital & Research Center

ClinicalTrials.gov Identifier:

[NCT01311050](#) [History of Changes](#)

Other Study ID Numbers:

RAC# 2081-068

RAC# 2081-068

First Posted:

March 9, 2011 [Key Record Dates](#)

Last Update Posted:

December 13, 2011

Last Verified:

December 2011

Keywords provided by King Faisal Specialist Hospital & Research Center:

Metastatic Colorectal Cancer

Additional relevant MeSH terms:

Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Bevacizumab
Capecitabine
Oxaliplatin
Irinotecan
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors

